In high-lev­el reshuf­fle, Roche gives James Sabry the glob­al reins on deal-mak­ing — over­see­ing pRED and gRED

In the 9 years since Roche bought up all of Genen­tech, the Swiss phar­ma gi­ant has been care­ful to leave its lega­cy R&D group pRED sep­a­rate from the folks at the gRED op­er­a­tions they ac­quired in San Fran­cis­co. But in a star­tling shift to­day the ex­ec­u­tive team knit­ted the two groups’ BD teams in­to one, com­bin­ing part­ner­ing ops and mak­ing Genen­tech’s James Sabry their glob­al deal czar for phar­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER